Cue Biopharma Inc (CUE) Stock Price, Quote & News

Company Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 949 2680

Website: www.cuebiopharma.com

Address:

40 Guest Street, Boston, United States

LabPsycho Mar. 18 at 6:40 PM

$CUE @Ron_Burn Nice call. This looks to me like yet another garden variety'biotech' using the over used move the past 4-5 years out of my yet to be published (hopefully) "BioGrifter's Wealth Transfer Vehicle Playbook" - May as well just dilute massively at your stock price's historical lows. There aint nothing your existing shareholders can do about it, so dilute, raise more $$$ for your salaries and benefits and be sure to chuckle while doing it.

0 · Reply

trading_momentum_x Mar. 18 at 9:58 AM

$CUE Bias: Downtrend / choppy Levels: R: 0.30 → 0.32 S: 0.27 → 0.25 Alpha: Fail 0.30 → continuation lower. Reclaim → bounce scalp only.

0 · Reply

SirDuncan Mar. 18 at 2:49 AM

$CUE just renewed all-time low

1 · Reply

VinWeezel Mar. 17 at 7:37 PM

$CUE bert

0 · Reply

taneraydar Mar. 17 at 5:58 PM

$CUE in @.272 shouldn’t be that low.

1 · Reply

SaySomethingNice Mar. 17 at 2:43 PM

$CUE this is the low, rn... Once the $LNAI profit takers coming here, soon...

0 · Reply

Ron_Burn Mar. 17 at 1:41 PM

$CUE i smell dilution

0 · Reply

SaySomethingNice Mar. 17 at 12:24 PM

$CUE SHE BELONGS WAY HIGHER THEN THIS.. A*STAR IS A HUGE ENTITY. PARTNERSHIP WITH COLLABORATION.. $15MM+ 👍 ROYALTIES $$$ 👍 AHEAD.. LOW : $.23 PPS. HIGH : $1.05 PPS. BUSINESS ON GOING, ON TARGET, 👍 CONTINUATION ONWARD 👍 PT, RN: SUPER FUNG CHEAP 👍

0 · Reply

Ron_Burn Mar. 17 at 12:15 PM

$CUE she's my next play $LNAI

0 · Reply

SaySomethingNice Mar. 17 at 11:10 AM

$CUE ( A*STAR ) IS GIGANTIC ENTITY... 👍

0 · Reply

Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 9, 2026, 8:00 AM EDT - 9 days ago

Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

Feb 17, 2026, 8:00 AM EST - 4 weeks ago

Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

Feb 12, 2026, 8:00 AM EST - 4 weeks ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

Dec 19, 2025, 8:00 AM EST - 3 months ago

Cue Biopharma Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 4:02 PM EST - 3 months ago

Cue Biopharma Announces Proposed Public Offering

Nov 12, 2025, 4:05 PM EST - 4 months ago

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 8:00 AM EST - 4 months ago

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Sep 29, 2025, 9:00 AM EDT - 6 months ago

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Aug 21, 2025, 8:00 AM EDT - 7 months ago

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

Aug 13, 2025, 8:00 AM EDT - 7 months ago

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 16, 2025, 8:00 AM EDT - 8 months ago

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Jul 1, 2025, 4:05 PM EDT - 9 months ago

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

Jun 24, 2025, 4:48 PM EDT - 9 months ago

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

May 12, 2025, 4:05 PM EDT - 11 months ago

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 11 months ago

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

May 5, 2025, 10:00 AM EDT - 11 months ago

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Apr 15, 2025, 6:12 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Apr 15, 2025, 2:00 AM EDT - 1 year ago

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Apr 14, 2025, 10:23 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Apr 14, 2025, 5:02 PM EDT - 1 year ago

Cue Biopharma to Host Business Update Call and Webcast

Mar 31, 2025, 4:20 PM EDT - 1 year ago

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Nov 29, 2024, 4:30 PM EST - 1 year ago

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:05 PM EST - 1 year ago

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

Cue Biopharma Announces Strategic Organizational Transition

Nov 8, 2024, 1:30 PM EST - 1 year ago

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 26, 2024, 11:26 PM EDT - 1 year ago

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Sep 26, 2024, 11:10 PM EDT - 1 year ago

Cue Biopharma Announces Proposed Public Offering

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Aug 19, 2024, 8:17 PM EDT - 1 year ago

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Aug 19, 2024, 4:05 PM EDT - 1 year ago

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 8:00 AM EDT - 2 years ago

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Apr 24, 2024, 10:01 AM EDT - 2 years ago

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2024, 9:43 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Feb 29, 2024, 10:00 AM EST - 2 years ago

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Nov 22, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Nov 11, 2023, 3:32 PM EST - 2 years ago

Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 8:00 AM EST - 2 years ago

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Aug 9, 2023, 10:23 PM EDT - 2 years ago

Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 7, 2023, 8:00 AM EDT - 3 years ago

Cue Biopharma to Host Investor Call

Jun 5, 2023, 8:00 AM EDT - 3 years ago

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 3 years ago

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

LabPsycho Mar. 18 at 6:40 PM

0 · Reply

trading_momentum_x Mar. 18 at 9:58 AM

$CUE Bias: Downtrend / choppy Levels: R: 0.30 → 0.32 S: 0.27 → 0.25 Alpha: Fail 0.30 → continuation lower. Reclaim → bounce scalp only.

0 · Reply

SirDuncan Mar. 18 at 2:49 AM

$CUE just renewed all-time low

1 · Reply

VinWeezel Mar. 17 at 7:37 PM

$CUE bert

0 · Reply

taneraydar Mar. 17 at 5:58 PM

$CUE in @.272 shouldn’t be that low.

1 · Reply

SaySomethingNice Mar. 17 at 2:43 PM

$CUE this is the low, rn... Once the $LNAI profit takers coming here, soon...

0 · Reply

Ron_Burn Mar. 17 at 1:41 PM

$CUE i smell dilution

0 · Reply

SaySomethingNice Mar. 17 at 12:24 PM

0 · Reply

Ron_Burn Mar. 17 at 12:15 PM

$CUE she's my next play $LNAI

0 · Reply

SaySomethingNice Mar. 17 at 11:10 AM

$CUE ( A*STAR ) IS GIGANTIC ENTITY... 👍

0 · Reply

Joyfulwood Mar. 17 at 9:39 AM

$CUE 0.29 dip SL under 0.26 Looking for consolidation near 0.30 PT 0.35/0.39/0.43/0.46/0.50+ Cue Biopharma Q4 And FY25 Collaboration Revenue Improves

0 · Reply

Ron_Burn Mar. 17 at 8:56 AM

$CUE possible entry here

0 · Reply

SaySomethingNice Mar. 17 at 7:26 AM

$CUE NO BS. JUST ROCK N ROLL TOMORROW 👍 #momo #fomo

0 · Reply

glaucio Mar. 17 at 6:41 AM

$CUE crap 💩 stock, . They are going to receive 1 digit royalties 🤣. Presentation was on 14/3 and they released their crap news on @16/3 after market closed 🥴 short that crap as a hell.

0 · Reply

Ron_Burn Mar. 17 at 6:41 AM

$CUE no live charts in the o/n sucks, but i can still read the price action and fib levels. starter between 0.28 and 0.30, crossing 0.32 - 0.34 zone would send her on the next run

0 · Reply

SaySomethingNice Mar. 17 at 5:28 AM

$CUE 🔥 W 🔥 formation forming... THAT MEANS BALSTOFF ON THE WAY... Over 30-35x tomes over the daily volumes. LOOKING FOREARD TO MORNINGS CONTINUATION OF SLAPPAGE $$$... - Imo...

0 · Reply

SaySomethingNice Mar. 17 at 4:24 AM

$CUE SINGAPORE, November 13, 2025--(BUSINESS WIRE)--ImmunoScape Pte. Ltd., ( an A*STAR spin out backed by Amgen Ventures 👍 and EDBi ) 👈 that is developing next-generation TCR-based cancer immunotherapies, today announced an exclusive in-licensing deal with Cue Biopharma Inc. (Nasdaq: CUE) to lead the development of a distinct new class of therapies to attack solid tumor cancers. The deal provides ImmunoScape with exclusive access to Cue Biopharma’s clinical-stage Immuno-STAT® molecules in oncology 🔥

0 · Reply

SaySomethingNice Mar. 17 at 1:02 AM

$CUE YAHOO FINANCE SHOW: .36+ JUST NOW!

0 · Reply

Frab Mar. 17 at 1:02 AM

$CUE

0 · Reply

SaySomethingNice Mar. 17 at 12:11 AM

$CUE Some people likes to scare with words like RS talk.. The annual meeting is April 12 and the voting needs to be approve ??? Regardless, that's a few weeks away.. Non-issue and not urgency of that talk.. - Imo.. ( nfa )

0 · Reply

SirDuncan Mar. 16 at 11:48 PM

$CUE very solid earnings, but a few things to remember: oncology progress was punted, autoimmune is still pre clinical with IND not yet approved, and a reverse split is proposed that will more than likely go into effect q2

0 · Reply

SaySomethingNice Mar. 16 at 11:24 PM

$CUE 👀 👈 $CDIO $MBOT $HURA Take a look at the news... 52-WEEK HIGH : $1.05 PPS. 52-WEEK LOW: $.23 PPS. WE KNOW BIOTECH, WITH SOLID NEWS, OR ANY MONSTER NEWS, SHE'S GONE.. 👍

0 · Reply

Market Cap	22.34M
Revenue (ttm)	9.29M
Net Income (ttm)	-40.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-437.78%
Debt to Equity Ratio	0.12

Volume	1,234,900
Avg Vol	1,626,182
Day's Range	N/A - N/A
Shares Out	78.74M
Stochastic %K	12%
Beta	1.51
Analysts	Strong Sell
Price Target	$3.33